Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale
about
Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapiesClinical manufacturing of CAR T cells: foundation of a promising therapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesNovel immunotherapies in lymphoid malignanciesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectChimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challengesManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesSmart CARs engineered for cancer immunotherapyEngineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategyRegression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacyL1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in MiceComparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.CAR T cells: driving the road from the laboratory to the clinic.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.New cell sources for T cell engineering and adoptive immunotherapy.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapySpotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs.Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.Tumor immunology: multidisciplinary science driving basic and clinical advances.Impact of T cell selection methods in the success of clinical adoptive immunotherapy.
P2860
Q22000626-DD70855F-DFE1-467A-B8F9-EE9DEA624F45Q26747037-20954C59-933D-46A6-8899-20D886146EF8Q26773309-BF6929E1-072D-414F-B749-C9F530D3388DQ26775720-50BE966F-004A-4DB6-9669-5D2730204207Q26777394-19DD80BB-A1F5-4B4E-B5FE-F332B96BF15CQ26826830-A1781F25-37CD-4EE2-96F7-03238C617C12Q27025300-66FCFF06-4CF8-48EF-AB4E-3BBD37087656Q28085769-9BDEBA24-D76A-466F-9401-F3830AED30E6Q28087236-68A0DCB4-C7DA-4CD1-B906-6FBAD7B4FF2DQ28533690-A720EAC8-DC7A-4CA7-A4DB-EBCE8430F3A1Q33561644-5D06351B-618C-457B-9F25-EC9BDCB342B5Q33749635-E79C4A5D-F4EF-4B15-B7CD-86BA0ECE43B1Q34041792-0A6AC03E-FEB5-436A-8162-4834D59CDFC3Q34069803-952B039D-AF38-486C-8A38-45E44BA95394Q35399080-AC5BF15A-84A3-463B-94FD-7B3D5B54BD1EQ35892897-18BF7319-8263-4D8F-A423-200FDC5F67AAQ36597392-62D7492A-80A3-4E54-9C44-29EBD1398798Q36951719-52471302-B4A8-4F71-8B9A-B7158FA45376Q37015682-749A38D6-659C-437A-AF0A-5346335AE157Q37257207-2FA578E3-DCBC-4EC1-AF93-623820778FA4Q37390239-AD0AC132-8DE1-4CDF-B2F7-623B4F658395Q37713393-6FB72F57-9E35-42C2-BF34-B6C20229D29FQ38170499-A06F185A-A697-41A7-A8A1-5454386E4A96Q38170500-2B367A77-0BF0-4FD1-8C66-5B290988BE1AQ38199350-E33E8231-E4AB-4DFA-9347-8C52EB794B6BQ38267385-EEAC9DFC-A012-476B-86F1-A1C0B53B7E17Q38406089-3C88DE47-0E2F-4E09-B8E7-D70C5433EF91Q38568358-57BAD011-A4BD-4B81-B500-AD18538A2378Q38666579-388522D3-9B28-4DDF-A0FA-17CC1F1CA8FBQ38674589-478FBF5C-BC5E-466D-9359-09379D1053EAQ38741113-91E229CC-8F66-4FF0-86A9-7DA11CC4FB97Q38777377-1F2F1EA7-1876-43A3-83B1-A8519499D160Q38786626-7B48C62D-9E1D-4603-B77E-A8979241E667Q38827775-324C478F-8CFB-4540-9C33-FAFF0D3716CCQ38912282-759C4188-F563-4536-9BD7-F618CAF4328DQ39003786-F555E901-BFFE-41F0-BE6B-C62D0ACBC47FQ40064246-C224C2D0-D50D-4230-9874-85F42A5FA518Q40183378-83501057-0764-470A-A531-AFBEE25E4C5DQ41853258-9C17EC7E-E2B0-4DD2-822C-8D6905A67F25Q42265908-E40CE0DF-A9E6-4C19-969A-31D2C863D58B
P2860
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phenotypic and functional attr ...... manufactured at clinical scale
@ast
Phenotypic and functional attr ...... manufactured at clinical scale
@en
type
label
Phenotypic and functional attr ...... manufactured at clinical scale
@ast
Phenotypic and functional attr ...... manufactured at clinical scale
@en
prefLabel
Phenotypic and functional attr ...... manufactured at clinical scale
@ast
Phenotypic and functional attr ...... manufactured at clinical scale
@en
P2093
P2860
P1476
Phenotypic and functional attr ...... manufactured at clinical scale
@en
P2093
Araceli Naranjo
Brenda Aguilar
Cherrilyn Bautista
Chinglam W Wong
Christine E Brown
Julie R Ostberg
Michael C Jensen
Stanley R Riddell
Stephen J Forman
Wen-Chung Chang
P2860
P304
P356
10.1097/CJI.0B013E318270DEC7
P577
2012-11-01T00:00:00Z